Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Nephron Clin Pract ; 127(1-4): 51-5, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25343821

RESUMEN

The immune system is among the key pathogenic factors in acute kidney injury (AKI). Various immune cells, including dendritic cells, natural killer T cells, T and B lymphocytes, neutrophils and macrophages are involved. Conventional CD4+ lymphocytes are well established to participate in early injury, and CD4+CD25+FoxP3 regulatory T cells are protective and can accelerate repair. A newly identified kidney T cell receptor + CD4-CD8- (double-negative) T cell has complex functions, including potentially anti-inflammatory roles in AKI. In this mini review, we summarize the data on the role of lymphocytes in AKI and set the stage for further mechanistic studies as well as interventions to improve outcomes.


Asunto(s)
Lesión Renal Aguda/inmunología , Subgrupos de Linfocitos T/inmunología , Lesión Renal Aguda/complicaciones , Lesión Renal Aguda/fisiopatología , Lesión Renal Aguda/terapia , Traslado Adoptivo , Animales , Antígenos CD/análisis , Antígeno B7-1/inmunología , Linfocitos T CD4-Positivos/inmunología , Quimiotaxis de Leucocito , Células Dendríticas/inmunología , Modelos Animales de Enfermedad , Humanos , Inflamación , Riñón/irrigación sanguínea , Riñón/fisiología , Macrófagos/inmunología , Ratones , Ratones Noqueados , Regeneración , Terapia de Reemplazo Renal , Daño por Reperfusión/inmunología , Linfocitos T Reguladores/inmunología
2.
Nefrologia ; 30(3): 349-53, 2010.
Artículo en Español | MEDLINE | ID: mdl-20514102

RESUMEN

Post-dilution on-line hemodiafiltration (OL-HDF) is the most efficient infusion mode to obtain maximum clearances of uremic toxins, with a recommended manual infusion flow (Qi) of 25% of the blood flow with the main limitation that causes alarms by hemoconcentration throughout the session. Recent technical advances allow automatic prescription of Qi if hematocrit and total protein (TP) values are specified. As these analytical results are not possible to obtain in each dialysis session, a practical way to prescribe Qi is to make an automatic prescription adjusting the hematocrit and total protein values at the beginning of the session to obtain the manual prescription required and we will call it automatic-manual prescription. The aim of this study was to compare manual Qi with automatic-manual Qi in postdilution OL-HDF. 30 patients (16 men and 14 women), 59.9 +/- 15 years old, in hemodialysis program for 50.1 +/- 67 months were included. Every patient underwent four OL-HDF sessions, two with manual Qi (4008-S and 5008 monitors) and two with automatic-manual Qi (A-M), one with the same Qi and one with manual Qi +20 (A-M+20). The same usual dialysis parameters were maintained: helixone dialyzer, dialysis time of 266 +/- 39 minutes, blood flow of 420 +/- 36. Recirculation, Kt and intradialysis alarms were measured at each session. No significant differences in the fistula recirculation or dialysis dose measured using Kt. Total infusion volume was 24.9 +/- 4 (4008 S), 23.4 +/- 4 L (5008) with manual Qi, 23.6 +/- 4 L (A-M) Qi (NS) and 25.8 +/- 5 L (A-M+20). Only 14% of patients had no incidents. The number of alarms was significantly higher with manual prescription 55 alarms with 4008 and 40 with 5008 vs. AM (11) p < 0.01) and A-M+20 (16 alarms) We concluded that automatic-manual Qi is a practical way for post-dilutional OL-HDF prescription where the same efficiency and total reinfusion volume with an important reduction of intradialysis alarms are obtained, allowing to rise Qi by 20% without increasing intradialysis alarms.


Asunto(s)
Hemodiafiltración/métodos , Fallo Renal Crónico/terapia , Prescripciones , Adulto , Anciano , Algoritmos , Automatización , Proteínas Sanguíneas/análisis , Alarmas Clínicas , Femenino , Hematócrito , Hemodiafiltración/instrumentación , Humanos , Masculino , Persona de Mediana Edad , Sistemas en Línea , Presión , Reología , Urea/análisis
3.
Transplant Proc ; 48(9): 3046-3052, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27932144

RESUMEN

BACKGROUND: Antibody-mediated response in solid organ transplantation is critical for graft dysfunction and loss. The use of immunosuppressive agents partially inhibits the B-lymphocyte response leading to a risk of acute and chronic antibody-mediated rejection. This study evaluated the impact of JAK3 and PKC inhibitors tofacitinib (Tofa) and sotrastaurin (STN), respectively, on B-cell proliferation, apoptosis, and activation in vitro. METHODS: Human B cells isolated from peripheral blood of healthy volunteers were cocultured with CD40 ligand-transfected fibroblasts as feeder cells in the presence of interleukin (IL) 2, IL-10, and IL-21. The cocultures were treated with immunosuppressants Tofa, STN, and rapamycin (as a control), to analyze the proliferation and apoptosis of B cells by means of Cyquant and flow cytometry, respectively. CD27 and IgG staining were applied to evaluate whether treatments modified the activation of B cells. RESULTS: Tofa and STN were able to inhibit B-cell proliferation to the same extent as rapamycin, without inducing cell apoptosis. After 6 days in coculture with feeder cells, all B cells showed CD27 memory B-cell phenotype. None of the immunosuppressive treatments modified the proportion between class-switched and non-class-switched memory B cells observed in nontreated cultures. The high predominance of CD27+CD24+ phenotype was not modified by any immunosuppressive treatment. CONCLUSIONS: Our results show that Tofa and STN can suppress B-cell antibody responses to an extent similar to rapamycin, in vitro; therefore these compounds may be a useful therapy against antibody-mediated rejection in transplantation.


Asunto(s)
Linfocitos B/efectos de los fármacos , Janus Quinasa 3/antagonistas & inhibidores , Piperidinas/farmacología , Proteína Quinasa C/antagonistas & inhibidores , Inhibidores de Proteínas Quinasas/farmacología , Pirimidinas/farmacología , Pirroles/farmacología , Quinazolinas/farmacología , Apoptosis/efectos de los fármacos , Linfocitos B/inmunología , Ligando de CD40/farmacología , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Humanos , Inmunosupresores/farmacología , Interleucina-10/farmacología , Interleucina-2/farmacología , Interleucinas/farmacocinética , Leucocitos Mononucleares/efectos de los fármacos , Activación de Linfocitos/efectos de los fármacos , Sirolimus/farmacología
4.
Nefrologia ; 31(6): 743-6, 2011.
Artículo en Inglés, Español | MEDLINE | ID: mdl-22130292

RESUMEN

Kidney involvement associated to lymphoma is a known phenomenon but frequently not characterized due to the low frequency with which biopsies are realized in these patients. Several histological patterns can co-exist and happen unnoticed without a biopsy. Parenchyma infiltration in kidney for lymphoma has been found in 34% (post-mortem) and 14% (pre-mortem) and have low incident of clinical manifestations. Other patterns of renal injury are associated to lymphoma and minimal changes disease is especially related with Hodgkin's lymphoma. Renal lesions associated to paraprotein in lymphoplasmacytic lymphoma are an exceptional association, in spite of in 20% of them, appear cryoglobulinemia. There are a few cases reported in the literature with different histological patterns: light-chain disease, amyloidosis, and immunotactoid glomerulopathy related with kidney injury in patients with lymphoma. A 39-year-old male presented an association among paraproteinemia, membrano-proliferative glomerulonephritis no hepatitis C virus related and lymphoplasmacytic lymphoma with renal infiltration. This case emphasized the variety of renal lesions that lymphomas could trigger and the value of the nephropathology in the diagnosis and outcome of the hematologic diseases with paraproteinemia.


Asunto(s)
Crioglobulinemia/etiología , Glomerulonefritis Membranoproliferativa/complicaciones , Riñón/patología , Macroglobulinemia de Waldenström/complicaciones , Adulto , Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Biopsia , Progresión de la Enfermedad , Edema/etiología , Glomerulonefritis Membranoproliferativa/sangre , Glomerulonefritis Membranoproliferativa/patología , Hepatitis C , Humanos , Masculino , Síndrome Nefrótico/etiología , Intercambio Plasmático , Proteinuria/etiología , Púrpura/etiología , Rituximab , Vasculitis/etiología , Macroglobulinemia de Waldenström/sangre , Macroglobulinemia de Waldenström/diagnóstico , Macroglobulinemia de Waldenström/tratamiento farmacológico , Macroglobulinemia de Waldenström/patología , Macroglobulinemia de Waldenström/terapia
5.
Transplant Proc ; 43(6): 2179-81, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21839227

RESUMEN

INTRODUCTION: The aim of this study was to evaluate the experience of a renal transplantation unit in the management of human immunodeficiency virus (HIV)-infected patients with end-stage renal disease (ESRD). METHODS: A prospective study was performed between 2005 and 2010 among 23 patients with ESRD. RESULTS: In this study 83% of HIV-infected patients with ESRD were included on the waiting list for renal transplantation with 4 patients in a clinical evaluation phase. During the follow-up, 52% of waiting list patients (n = 11) received a renal transplant, and 1 patient underwent a simultaneous kidney-pancreas transplantation. Among the waiting list group we observed a significant later exclusion (43%; n = 3). Among the transplanted group there was a high but clinically inconsequential prevalence of acute tubular necrosis (36%; n = 4) and acute rejection episodes (36%; n = 4). The renal function showed a serum creatinine of 1.1 mg/dL at a follow-up of 24 + 12 months. All patients on the waiting list and after the transplantation are prescribed combined antiretroviral treatment (cART) with a low viral load <50 with CD4 >200. CONCLUSIONS: HIV-infected patients with ESRD should be considered to be candidates for renal transplantation if they meet the HIV inclusion criteria. Renal transplantation in adequately selected HIV-infected patients is a safe procedure with acceptable patient and graft survivals.


Asunto(s)
Infecciones por VIH/complicaciones , Fallo Renal Crónico/cirugía , Trasplante de Riñón , Listas de Espera , Adulto , Fármacos Anti-VIH/uso terapéutico , Biomarcadores/sangre , Creatinina/sangre , Femenino , Rechazo de Injerto/sangre , Rechazo de Injerto/inmunología , Supervivencia de Injerto , Infecciones por VIH/diagnóstico , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/mortalidad , Humanos , Fallo Renal Crónico/complicaciones , Trasplante de Riñón/efectos adversos , Trasplante de Riñón/inmunología , Trasplante de Riñón/mortalidad , Necrosis Tubular Aguda/etiología , Masculino , Persona de Mediana Edad , Selección de Paciente , Estudios Prospectivos , España , Análisis de Supervivencia , Tasa de Supervivencia , Factores de Tiempo , Resultado del Tratamiento , Listas de Espera/mortalidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA